Peptide policy covers the rules that decide which peptides patients can get legally, and from whom. After the FDA placed BPC-157 and other injectable peptides in Category 2 in 2023, compounding pharmacies largely stopped making them, and demand shifted to "research use only" sellers.
In 2026 much of that reversed. The FDA removed epitalon and other peptides from Category 2 effective April 22. In July, the Pharmacy Compounding Advisory Committee recommended six of seven peptides for the 503A bulks list, against the advice of FDA career staff. On October 28, HHS said it would not take enforcement action against 503A pharmacies that compound BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax. The policy is not an approval and leaves out larger 503B facilities. It ran in the Federal Register on October 30, with comments due November 13.
Stories here cover those moves and the fight over them, from the Alliance for Pharmacy Compounding, which calls the policy a more accountable alternative, to critics such as Public Citizen. See #category-2, #peptide-regulation, #compounding, and #fda.
HHS published its enforcement discretion policy for 503A compounding with six peptide bulk substances in the Federal Register on October 30, 2026, under docket HHS-OASH-2026-0496, with written comments accepted for two weeks, through November 13. The notice calls the policy a draft and interim, says it is not binding, and says HHS may revisit it in whole or in part if a safety signal or product quality issue arises; FDA rulemaking on the 503A bulks list may later propose adding some or all of the peptides.
Citing six people familiar with the policy, the Associated Press reported that HHS first wanted the FDA to write a rule adding BPC-157 and other peptides to the list of substances safe for compounding, then switched to a promise not to enforce after agency scientists would not support it. FDA staff did get some safeguards added: ingredients from FDA-registered factories, side-effect reporting, and purity checks. Former FDA official Peter Lurie said the agency lacks the legal authority to enforce those pharmacy requirements.
NPR reported Oct. 28 that HHS will not take enforcement action against small 503A compounding pharmacies that make BPC-157, TB-500, epitalon, KPV, MOTS-c, and semax. The policy is not an FDA approval and does not cover larger 503B outsourcing facilities; FDA scientists had recommended against lifting the restrictions in July. Public Citizen's Dr. Robert Steinbrook said Secretary Robert F. Kennedy Jr. "has undermined the FDA," while the president of a Florida compounding pharmacy told NPR, "We won't be able to meet demand."
President Trump announced Wednesday August 19, 2026 the formal nomination of Dr. Heidi Overton, a physician who currently works as deputy assistant to the president for domestic policy and formerly chief policy officer at America First Policy Institute, to serve as the next commissioner of the U.S. Food and Drug Administration. If confirmed by the U.S. Senate, Overton would take over from Kyle Diamantas (JD), who has served as acting commissioner since May 2026 following the departure of Marty Makary. Overton holds an MD from the University of New Mexico and a PhD in clinical investigation from Johns Hopkins Bloomberg School of Public Health, and served in the first Trump administration in the Office of American Innovation and Domestic Policy Council. She is Trump's third choice for the position after former Rep. Brad Wenstrup (R-Ohio) and acting Commissioner Diamantas both declined. The nomination matters for peptide-industry readers because the FDA rulemaking to translate the July 23-24 PCAC 6-peptide 503A recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon) into a proposed rule (and eventually a final rule) will run through Overton's tenure if she is confirmed; the February 2027 PCAC meeting on cathelicidin, GHK-Cu, dihexa acetate, melanotan II, and PEG-MGF falls entirely within the window.
STAT News' Pharmalot newsletter reported Wednesday-Thursday July 8-9, 2026 that the White House is reviewing three finalists to lead the FDA following the departure of the prior commissioner earlier in 2026: Heidi Overton, a policy adviser in the White House itself; Jeffrey Vacirca, an oncologist and health-system executive; and Stephen Ferrara, a health official at the Department of Defense. Axios first surfaced the shortlist on June 26; the July 8-9 STAT reporting confirmed the trio is under active White House review with a decision expected in the coming weeks. The peptide policy trajectory tracks through whichever nominee advances. FDA career-staff briefing documents released June 29-30 concluded all seven PCAC peptides have insufficient evidence for 503A eligibility, while HHS Secretary RFK Jr.'s public push points the other direction; the incoming commissioner will inherit an agency-vs-secretary tension around peptide compounding as the July 23-24 PCAC vote lands. The nominee will also inherit the pending Novo Nordisk-Vivani semaglutide-implant evaluation agreement, the Sandoz generic-tirzepatide ANDA acceptance from June 29, and the ongoing 503B GLP-1 exclusion rulemaking.
The Hill ran a Washington-policy framing of the July 23-24 PCAC peptide-compounding meeting, casting the agenda as the regulatory follow-through on HHS Secretary Robert F. Kennedy Jr.'s repeated pledges to ease access to wound-healing, weight-loss, and longevity peptides favored by the Make America Healthy Again movement. The committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon. Written comment closes July 9; oral-presentation requests close June 30, eighteen days from today.
The FDA updated its Section 503A bulks drug substances list on May 14, 2026, continuing the rolling-status changes leading into the July 23-24 PCAC meeting that will evaluate seven peptides (BPC-157, KPV, TB-500, MOTs-C on Day 1; Emideltide/DSIP, Semax, Epitalon on Day 2) for potential 503A-bulks-list inclusion. The April 30 503B bulks-list proposal (closing June 29) is moving in parallel toward effectively ending large-scale 503B compounding of semaglutide, tirzepatide, and liraglutide. The combined regulatory cycle through July 24 will reshape the compounding-pharmacy economy for the next 2-3 years and determine which research peptides remain accessible through licensed channels.
Foley & Lardner published a May 2026 client memo translating the FDA's April 22 Category 2 removal of 12 peptides for the compounding-pharmacy audience. Key framing: the removal does not, by itself, place these substances on the 503A bulks list, and the peptides will exist in a regulatory gray zone until the PCAC meets July 23–24 to consider seven of them (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon) and the FDA takes final action — which under standard rulemaking timelines could run more than a year past the meeting. The piece joins the Orrick May 2026 503B GLP-1 memo, the FDA Law Blog Pep(tide) Rally analysis (April 23), Holt Law's California Sherman-Law alert, and the Frier Levitt April peptide update as the legal cluster compounders are reading ahead of the meeting.
Drexel University's news desk ran a May 5 Q&A on peptide popularity and safety, framed by the FDA's April Category 2 removals and the upcoming July 23–24 PCAC meeting on seven peptides for the 503A bulks list. The piece covers why peptides are surging — easier and cheaper synthesis since the 1980s genetic-engineering era, plus newer molecules like GLP-1 with broad therapeutic effects — and the safety gaps: pharmacy-to-pharmacy compounding variability, supply not keeping up with demand, and a gray-market problem that pushes patients to unverified online sources. The Q&A joins the AMA, AJMC, Pharmacy Times, MIT Technology Review, and the American Council on Science and Health pieces in the post-Category-2 consumer-education ecosystem.
FormBlends and the FDA Law Blog 'Pep(tide) Rally' analyses surfaced a state-level compliance map that compounders are now navigating ahead of the July PCAC. California's Board of Pharmacy has issued 30+ enforcement actions against peptide-compounding pharmacies since 2023, scrutinizing both quality and technical regulatory compliance. Texas Board of Pharmacy enforcement has historically focused on egregious quality violations rather than minor technical issues, making the state more accessible for licensed 503A and 503B operations under physician prescription. The gap matters because telehealth platforms route fulfillment through state-by-state pharmacy networks; a CVS or compounder routing decision in 2026 is now a state-policy decision as much as a federal one.
Hello Peptide announced an expansion of its digital platform HelloPeptide.net on April 30, positioning it as a research-aligned consumer education resource for adults navigating GLP-1 and peptide-therapy decisions. The launch is timed to a documented surge in consumer search and telehealth inquiries that followed the FDA's April 22 Category 2 removal of 12 peptides and the upcoming July 23–24 PCAC meeting. The platform sits alongside FormBlends' 2026 State of Peptides report and a wave of legacy-media safety primers as the post-restriction information ecosystem takes shape.
Pharmacy law firm Holt Law published a detailed regulatory analysis of how the FDA's April 22 Category 2 removals interact with state pharmacy boards, 503A vs 503B compounding pathways, and physician prescribing requirements. The analysis emphasizes that Category 2 removal is not the same as 503A bulk-list inclusion, and that compounding pharmacies face material legal risk if they begin producing reclassified peptides before the July 23-24 PCAC meeting. The piece is a working reference for pharmacy operations preparing for the post-PCAC environment.
JustCare Health published a substantial analysis of the FDA's evolving peptide stance, framing the Category 2 removal as a practical inflection point that begins to resolve the gray-market dynamic that built up after the 2023 restrictions. The piece documents the Alliance for Pharmacy Compounding's position and emphasizes the gap between compounding-pharmacy operational readiness and patient demand. The piece is among the most-read peptide policy articles in the consumer-health press this week.